Replies to post #204502 on Biotech Values

[DewDiligence]

OCRX—...no serious [drug-related] safety issues [in the phase-2a NIH trial].

Good news, but not surprising insofar as most of the patients in the phase-2a NIH trial used a smaller daily dose of OCR-002 than is being used in OCRX's own STOP-HE trial.